November 12th, 2026Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities PersistNational registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.Read more
November 10th, 2026FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid TumorsThe FDA approved the PCR-based OncoMate MSI Dx Analysis System to identify patients with microsatellite instability–high solid tumors who may be eligible for pembrolizumab.Read more